USD 0.0
(14.29%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -38.31 Thousand USD | -362.12% |
2022 | -7573.00 USD | 88.13% |
2021 | -71.38 Thousand USD | -45.73% |
2020 | -47.3 Thousand USD | 21.16% |
2019 | -60.99 Thousand USD | 14.79% |
2018 | -71.32 Thousand USD | -14.79% |
2017 | -62.13 Thousand USD | 85.11% |
2016 | -419.18 Thousand USD | 0.0% |
2007 | -1.28 Million USD | 48.38% |
2006 | -2.31 Million USD | -365.62% |
2005 | -565.01 Thousand USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -630.00 USD | -21.15% |
2024 Q1 | -520.00 USD | 79.2% |
2024 Q3 | -664.00 USD | -5.4% |
2023 Q3 | -14.13 Thousand USD | -16.01% |
2023 Q4 | -2500.00 USD | 82.31% |
2023 Q1 | -9490.00 USD | -372.14% |
2023 Q2 | -12.18 Thousand USD | -28.35% |
2023 FY | - USD | -362.12% |
2022 Q1 | -2930.00 USD | 92.26% |
2022 Q3 | -2330.00 USD | -126.21% |
2022 Q2 | -1030.00 USD | 64.85% |
2022 Q4 | -2010.00 USD | 13.73% |
2022 FY | - USD | 88.13% |
2021 Q4 | -37.85 Thousand USD | -455.8% |
2021 FY | - USD | -45.73% |
2021 Q3 | -6810.00 USD | 0.0% |
2021 Q1 | -10.58 Thousand USD | 0.0% |
2020 FY | - USD | 21.16% |
2019 FY | - USD | 14.79% |
2018 FY | - USD | -14.79% |
2017 FY | - USD | 85.11% |
2016 FY | - USD | 0.0% |
2008 Q1 | -416.57 Thousand USD | 5.04% |
2007 FY | - USD | 48.38% |
2007 Q4 | -438.68 Thousand USD | -72.15% |
2007 Q3 | -254.82 Thousand USD | 25.08% |
2007 Q2 | -340.11 Thousand USD | -92.53% |
2007 Q1 | -176.65 Thousand USD | 43.52% |
2006 Q4 | -312.77 Thousand USD | -85.05% |
2006 Q2 | -196.97 Thousand USD | -114.88% |
2006 Q1 | 1.32 Million USD | 0.0% |
2006 Q3 | -169.02 Thousand USD | 14.19% |
2006 FY | - USD | -365.62% |
2005 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
China Medicine Corporation | 13.27 Million USD | 100.289% |
DH Enchantment Inc. | -145.23 Thousand USD | 73.621% |
Exlites Holdings International, Inc. | -90.49 Thousand USD | 57.665% |
One Step Vending Corp. | -26.55 Thousand USD | -44.283% |
MediPal Holdings Corporation | 431.52 Million USD | 100.009% |
PD-Rx Pharmaceuticals, Inc. | -51.41 Thousand USD | 25.494% |
Pharmagen, Inc. | -2.89 Million USD | 98.676% |
Suzuken Co., Ltd. | 340.78 Million USD | 100.011% |